• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Surf Bio raises $16M seed round for polymer-based drug delivery platform, rapid insulin

April 12, 2022 By Sean Whooley

Surf BioSurf Bio announced today that it raised $16 million in seed funding to advance its drug delivery offerings for treating diabetes.

Palo Alto, California-based Surf Bio plans to use the funds to advance its polymer-based drug delivery platform and accelerate the development of ultra-rapid insulin for treating diabetes.

According to a news release, Breakout Ventures and the Perceptive Xontogeny Venture Fund (PXV) co-led the financing. Additionally, Surf Bio added Breakout Ventures Managing Partner Lindy Fishburne and PXV Partner Ben Askew to its board of directors. They join current members and founders, Bryan Mazlish — a co-founder of Bigfoot Biomedical — and former Livongo CMO and Mode AGC co-founder Dr. Jennifer Schneider.

“Surf Bio’s novel stabilization platform holds the promise to enable pharmaceutical formulations that are not currently possible with today’s technologies,” Mazlish, Surf Bio’s co-founder and CEO said in the release. “Our technology enhances the stability of a broad set of biologics including peptides, vaccines, and monoclonal antibodies to retain or optimize desired pharmaceutical properties at higher concentrations and higher temperatures. This should enable favorably differentiated products that create new opportunities for how biologics are delivered in the future.”

The company said it has established a number of collaborations with leading pharmaceutical companies. The company’s demonstrated in-vitro and in-vivo safety and efficacy data has generated significant interest from partners, the company noted. Initial applications for the technology include increasing concentrations and reducing refrigeration dependence along with enabling hard-to-formulate therapeutics.

“Surf Bio’s technology sits at the intersection of engineering, chemistry, and pharmaceutical development,” Fishburne said. “We are pleased to support the company as it advances its broadly applicable formulation technology across a range of therapeutic areas for the potentially large positive impact it may have on human health.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: Surf Bio

IN CASE YOU MISSED IT

  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS